Nasus Pharma Ltd. — Company profile
Healthcare · Drug Manufacturers - General · Israel
Last price 3.07 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 35.96M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Details
| Name | Nasus Pharma Ltd. |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Employees | 7 |
| Founded | 2019 |
| Ipo Date | 2025-08-14 |
| Ceo | Brendan O'Grady |
| Country | Israel |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 8.00 |
| Isin | IL0012181553 |
| Cik | 2029039 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Brendan P. O'Grady | Chief Executive Officer and Director |
| Ehud Moshe Gilboa MBA | Co-Founder and Executive Chairman |
| Dr. Dalia Megiddo M.B.A., M.D., Ph.D. | Co-Founder, Director, Chief Medical Officer and Chief Development Officer? |
| Dr. Galia Temtsin Kryaz Ph.D. | Director of CMC and Product Development |
Contact
| Address | Yigal Alon 65, Tel Aviv-Yafo, 6744317, Israel |
| Phone | 972 3 573 6632 |
| Website | https://www.nasuspharma.com |